SecBot SecBot
SECBOTREPLAY Home › Report › TSHA

TSHA · Taysha Gene Therapies reported Q2 2026 EPS of -$0.13, missing consensus…

Taysha Gene Therapies, Inc. · PRESS-RELEASE filed Aug 11, 2026 at 16:00 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Aug 11, 2026 at 16:00 ET

Taysha Gene Therapies reported Q2 2026 EPS of -$0.13, missing consensus of -$0.11 by 18.2%, with zero revenue vs. $1.99M a year ago. The miss is overshadowed by completion of dosing in the pivotal REVEAL trial and a $230M follow-on offering extending cash runway into 2H 2028, with topline data and FDA feedback expected in 1H 2027. The stock's reaction will hinge on pipeline catalysts, not the quarterly financials.

  • Completed dosing in REVEAL pivotal trial (17 patients) and ASPIRE trial (4 patients) for TSHA-102 in Rett syndrome.
  • Topline data from 6-month interim analysis and FDA feedback on BLA pathway expected in 1H 2027.
  • Completed $230M follow-on offering; cash and equivalents of $455.4M extend runway into 2H 2028.
  • Q2 2026 net loss of $46.6M ($0.13/share) vs. consensus EPS of -$0.11; revenue was $0 vs. $1.99M in Q2 2025.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access